10x Genomics (TXG) Free Cash Flow (2018 - 2026)

10x Genomics (TXG) has 9 years of Free Cash Flow data on file, last reported at $26.0 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 19.89% year-over-year to $26.0 million; the trailing twelve-month figure through Mar 2026 stood at $123.7 million (up 123.23% YoY), and the FY2025 full-year result was $130.1 million, up 2348.99% from the prior year.
• Free Cash Flow declined to $26.0 million in Q1 2026, from $35.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $43.4 million in Q3 2025 to a low of -$48.9 million in Q1 2022.
• A 5-year average of -$4.0 million and a median of -$8.7 million in 2023 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow tumbled 228.18% in 2022 and jumped 2116.54% in 2025, its largest moves.
• Tracing TXG's Free Cash Flow over 5 years: stood at -$26.0 million in 2022, then advanced by 23.33% to -$19.9 million in 2023, then soared by 107.91% to $1.6 million in 2024, then jumped by 2116.54% to $35.0 million in 2025, then dropped by 25.66% to $26.0 million in 2026.
• Business Quant data shows TXG's Free Cash Flow at $26.0 million in Q1 2026, $35.0 million in Q4 2025, and $43.4 million in Q3 2025.